Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Regeneron Pharmaceuticals Inc (OQ:REGN)

Business Focus: Bio Therapeutic Drugs

INK Edge Outlook

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEC Form 4 filings for REGN*US within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Oct 21, 2020 18:41 ET
Scott+Scott Attorneys at Law LLP Continues to Investigate Regeneron Pharmaceuticals, Inc.’s Directors and Officers for Breach of Fiduciary Duty (REGN)
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a national securities and consumer rights litigation firm, continues to investigate whether certain directors and officers of Regeneron Pharmaceuticals, Inc. (“Regeneron”) (NASDAQ: REGN) breached their fiduciary duties to Regeneron and
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
0.39
--
--
Price to Sales - TTM
7.79
8.40
5.02
Price to Book - most recent quarter
6.86
3.58
3.33
Price to Cash Flow per share - TTM
19.44
12.67
15.66
Price to Free Cash Flow per share - TTM
25.69
16.46
25.70
See all valuations

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.

See business summary

 

Twitter

Search (past week) for $REGN